EDGAR Filing Documents for 0001144204-13-016755

Form POS AM - Post-Effective amendments for registration statement:

SEC Accession No. 0001144204-13-016755

Filing Date

2013-03-22

Accepted

2013-03-21 20:31:59

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	POS AM	v338850_posam.htm	POS AM	1722454
2	EXHIBIT 4.33	v338850_ex4-33.htm	EX-4.33	224511
3	EXHIBIT 4.34	v338850_ex4-34.htm	EX-4.34	115335
4	EXHIBIT 4.35	v338850_ex4-35.htm	EX-4.35	120424
5	EXHIBIT 4.36	v338850_ex4-36.htm	EX-4.36	114772
6	EXHIBIT 4.37	v338850_ex4-37.htm	EX-4.37	113524
7	EXHIBIT 4.38	v338850_ex4-38.htm	EX-4.38	168133
8	EXHIBIT 4.39	v338850_ex4-39.htm	EX-4.39	150913
9	EXHIBIT 23.1	v338850_ex23-1.htm	EX-23.1	2882
10	GRAPHIC	tlogo2.jpg	GRAPHIC	14258
	Complete submission text file	0001144204-13-016755.txt		2753704

Mailing Address C/O MARK COHEN, CHAIRMAN, PEARL COHEN 1500 BROADWAY, 12TH FLOOR NEW YORK NY 10036

Business Address 53 DAVIES STREET LONDON X0 W1K 5JH 646-878-0804

Morria Biopharmaceuticals PLC (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: POS AM | Act: 33 | File No.: 333-185247 | Film No.: 13708956
SIC: 2834 Pharmaceutical Preparations